Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

US10988487B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Kun Liu · Edison, US
• Abdelghani Achab · Melrose, US
• Purakkattle Biju · Piscataway, US
• Timothy A. Cernak · Boston, US
• Yongqi Deng · Newton, US
• Xavier Fradera · Brookline, US
• Liangqin Guo · Edison, US
• Yongxin Han · Kirkland, CA
• Shuwen He · Fanwood, US
• Joseph A. Kozlowski · Princeton, US
• Derun Li · Dedham, US
• Guoqing Li · Montgomery, US
• Qinglin Pu · Needham, US
• Zhi-Cai Shi · Monmouth Junction, US
• Wensheng Yu · Edison, US
• Hongjun Zhang · Waterloo, CA

Key dates

• Filing date: Aug 24, 2017
• Grant date: Apr 27, 2021
• Expiry date: Dec 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/0836
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.